The Genetics of Heart & Vascular Disease is organized by Mayo Clinic and will be held from Oct 12 - 13, 2018 at The Westin Hilton Head Island Resort and Spa, Hilton Head Island, South Carolina, United States of America.
The target audience for this medical event is pediatric and adult cardiologists, internists, primary care providers, and nurse practitioners with special interest in the management of patients with CVD, pediatric and adult cardiology trainees, and genetic counselors with an interest in cardiology. This CME Conference has been approved for a maximum of 12.50 AMA PRA Category 1 Credits.
This 1½ day CME course is to have experts in the field of cardiovascular genetics detail the important role of genetics, genomics, and pharmacogenetics in the diagnosis, risk stratification, and treatment of diseases affecting the heart and the blood vessels.
Topics will include: Genetics/Genomics 101, pharmacogenetics, gene risk scores, genetic purgatory, the molecular autopsy, and the diagnostic, prognostic, and therapeutic implications of genetic testing for patients with congenital heart disease, long QT syndrome and the other channelopathies, hypertrophic cardiomyopathy and the other cardiomyopathies, coronary heart disease, hyperlipidemias, heart failure, pulmonary hypertension, and the aortopathies.
Unique Features: Audience response system to enhance immediate feedback. Easy access to faculty members. One-on-one interaction. Efforts will be made to introduce the clinical applications using new technology, however, there is no hands-on experience provided. Self-assessment questions to gage outcome. A special workshop will be provided to analyze a genetic test report and to comment on the significance of genetic test results from your patients.
Upon conclusion of this program, participants should be able to:
• Summarize the probabilistic nature of genetic testing and develop a strategy to manage the variant of uncertain significance (VUS) test result
• Identify the impact of genetic testing in the diagnosis, risk stratification, and treatment of patients with heritable cardiomyopathies, channelopathies, and aortopathies
• Determine the role of genetic testing in children and adults with congenital heart disease
• Define genetic markers of atherosclerosis and the role of genetic risk scores (GRS) in risk stratification of coronary heart disease
• Identify the genetic basis of heritable causes of the hyperlipidemias and implications for prevention and familial screening
• Define the role of inheritance in cardiovascular drug response and to utilize genetics to minimize adverse events and maximize drug efficacy
Additional details will be posted as soon as they are available.
|Registration Type||End Date||Price|
|MD, PhD, DO, Pharm D - Early Fee||28 Sep,2018||USD 575.00|
|MD, PhD, DO, Pharm D - Regular Fee||11 Oct,2018||USD 675.00|
|Fellow, Resident, NP, PA, RN - Early Fee||28 Sep,2018||USD 450.00|
|Fellow, Resident, NP, PA, RN - Regular Fee||11 Oct,2018||USD 550.00|
The Westin Hilton Head Island Resort and Spa
2 Grasslawn Avenue
Hilton Head Island, South Carolina, United States Of America
The Westin Hilton Head Island Resort & Spa,
Two Grasslawn Ave,
Hilton Head Island, South Carolina, United States of America 29928,